JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB261878

Human CD9 knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

CD9 KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9 X = 7 bp deletion 1 bp deletion Frameshift = 100%. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Next Generation Sequencing - Human CD9 knockout A549 cell line (AB261878)
  • NGS

Supplier Data

Next Generation Sequencing - Human CD9 knockout A549 cell line (AB261878)

Knockout achieved by CRISPR/Cas9; X = 7 bp deletion, 1 bp deletion; Frameshift = 100%

Next Generation Sequencing - Human CD9 knockout A549 cell line (AB261878)
  • NGS

Supplier Data

Next Generation Sequencing - Human CD9 knockout A549 cell line (AB261878)

7 bp deletion (allele 1) and 1 bp deletion (allele 2) after Ile30 of the WT protein

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Next Generation Sequencing,Western blot

Mutation description

Knockout achieved by CRISPR/Cas9 X = 7 bp deletion 1 bp deletion Frameshift = 100%

Disease

Carcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab261878-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab261878 Human CD9 knockout A549 cell line", "number":"AB261878-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab259777 Human wild-type A549 cell line", "number":"AB261878-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab261878-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab261878 Human CD9 knockout A549 cell line", "number":"AB261878-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
CD9
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing, Western blot
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CD9 also known as motility-related protein-1 (MRP-1) is a transmembrane glycoprotein with a molecular weight of approximately 24 kDa. This protein is part of the tetraspanin family and shows widespread expression throughout different tissues including hematopoietic and non-hematopoietic cells. CD9 participates in numerous cellular processes by interacting with integrins and other cell surface receptors facilitating the organization of molecular complexes within the cell membrane.
Biological function summary

The CD9 protein is integral to cell adhesion migration and fusion. It forms complexes with other tetraspanins and proteins like EWI-2 and EWI-F contributing to cellular signaling and membrane compartmentalization. Additionally CD9 plays an important role in the formation and secretion of exosomes tiny vesicles emitted by cells that mediate cell-to-cell communication. These exosomes can be analyzed using tools like exosome assays and detection kits that target CD9 proteins.

Pathways

CD9 is involved in the regulation of immune response and cell morphology. It participates in pathways such as the integrin signaling pathway and the phosphatidylinositol 3-kinase (PI3K) signaling pathway. CD9 modulates these interactions by associating with proteins such as integrins and other members of the tetraspanin family influencing cellular movement and proliferation.

CD9 has connections to various conditions including cancer and infectious diseases. In cancer CD9 can influence tumor progression and metastasis while its altered expression levels have been associated with different cancer types. CD9 interacts with proteins such as integrins and CD81 in these contexts affecting cellular adhesion and migration mechanisms. In infectious diseases CD9 is involved in viral entry processes as some viruses utilize CD9 and its associated tetraspanins for entry into host cells.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com